1343. Clearance of Staphylococcus aureus Bacteremia in Patients Treated with Dalbavancin
Session: Poster Abstract Session: Clinical Trials
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • Clearance_Poster_FINAL_IDSA.pdf (88.2 kB)
  • Background:

    Dalbavancin is a lipoglycopeptide being studied for treatment of acute bacterial skin and skin structure infections (abSSSI).  It has potent activity against gram positive pathogens associated with abSSSI including both methicillin sensitive and methicillin resistant S. aureus.  We examined the clearance of bacteremia in four clinical studies of dalbavancin including three phase 3 trials in skin and skin structure infections and one phase 2 catheter related infection study.

    Methods:

    Patients in whom S. aureus was identified in blood cultures taken at the baseline visit were selected for further assessment.  Clearance of bacteremia is provided for those patients with at least one of the required follow-up post-baseline blood cultures. Comparators included vancomycin and linezolid (cSSSI).

    Results:

    Documented clearance of S. aureus bacteremia

    Infection

    Dalbavancin

    Comparator

    abSSSI

     

     

    DISCOVER 1

    3/3

    2/3

    DISCOVER 2

    7/7

    6/6

    Catheter related bloodstream infection

    10/10

    9/9

    cSSSI

    4/4

    2/2

     

     

     

    Total

    24/24 (100%)

    19/20 (95%)

    All patients with S. aureus bacteremia treated with dalbavancin for whom follow-up blood culture results were available cleared their bacteremia. One case of persistent bacteremia was from a patient treated with vancomycin. Both patients treated with linezolid had cleared their bacteremia.

    Conclusion:

    All patients treated with dalbavancin who had a S. aureus bacteremia associated with either a catheter or a skin infection and had follow up blood cultures available for evaluation in this series of clinical trials were documented to have had clearance of their bloodstream infection.

    Michael Dunne, MD, Durata Therapeutics, Inc., Branford, CT and Sailaja Puttagunta, MD, Durata Therapeutics, Branford, CT

    Disclosures:

    M. Dunne, Durata Therapeutics: Employee and Shareholder, Salary

    S. Puttagunta, Durata Therapeutics: Employee and Shareholder, Salary

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.